Loading…
CEL-SCI Corporation is projected to rise to $1.62 by 2027, a +30% move from its current price of $1.25. CVM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.19 | $1.25 | $1.31 | -0.02% |
| Aug 6 | $1.17 | $1.25 | $1.34 | -0.04% |
| Aug 7 | $1.15 | $1.25 | $1.36 | -0.06% |
| Aug 8 | $1.14 | $1.25 | $1.37 | -0.08% |
| Aug 9 | $1.12 | $1.25 | $1.39 | -0.10% |
| Aug 10 | $1.11 | $1.25 | $1.40 | -0.12% |
| Aug 11 | $1.10 | $1.25 | $1.41 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.10 | $1.25 | $1.41 | -0.13% |
| Week 2 | $1.04 | $1.25 | $1.49 | -0.27% |
| Week 3 | $1.00 | $1.24 | $1.55 | -0.40% |
| Week 4 | $0.9681 | $1.24 | $1.60 | -0.54% |
| Week 5 | $0.9387 | $1.24 | $1.64 | -0.67% |
| Week 6 | $0.9127 | $1.24 | $1.68 | -0.81% |
| Week 7 | $0.8894 | $1.24 | $1.72 | -0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CEL-SCI Corporation is a clinical-stage biotechnology company focused on research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. Its LEAPS technology, including CEL-2000, CEL-4000, and CEL-5000, is in preclinical trials, and the company has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
CEL-SCI Corporation (CVM) operates in the Healthcare sector with a current price of $1.18. The stock trades in a small-cap niche, reflecting its early-stage clinical trial status. Its market position is modest, with a market capitalization of $20.62M and a rank of 4643.
A major floor 40.8% below — a decisive break under it would weaken the trend.
The nearest floor, 22.4% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 296.0% above — clearing it would confirm fresh momentum.
Key CVM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.18 | Buy | $1.18 | Buy |
| MA 10 | $1.20 | Buy | $1.19 | Buy |
| MA 20 | $1.23 | Buy | $1.20 | Buy |
| MA 50 | $1.24 | Buy | $1.45 | Sell |
| MA 100 | $2.18 | Sell | $2.24 | Sell |
| MA 200 | $4.13 | Sell | $4.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.18 | Neutral |
| Stoch RSI (14) | 29.22 | Neutral |
| CCI (20) | -72.58 | Neutral |
| Williams %R (14) | -84.62 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 0.87 | Buy |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 15.38 | Buy |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 41.65 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.17 | Buy |
| ADX (14) | 13.19 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 50. The stock trades around the SMA50 of $1.26, well below the SMA200 of $4.40, suggesting limited near-term upside pressure. Support is $0.97 and resistance is $1.41, framing a 30-day range from $0.839 to $1.66.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.97 | $1.25 | $1.62 | 0% | Neutral | |
| $1.21 | $1.62 | $2.34 | +30% | Bullish | |
| $1.26 | $1.78 | $2.73 | +43% | Bullish | |
| $0.9536 | $1.41 | $2.27 | +13% | Neutral | |
| $0.9202 | $1.42 | $2.36 | +13% | Neutral | |
| $0.9125 | $1.46 | $2.51 | +17% | Neutral | |
| $0.895 | $1.48 | $2.63 | +19% | Neutral | |
| $1.17 | $2.00 | $3.64 | +60% | Bullish | |
| $1.13 | $2.00 | $3.72 | +60% | Bullish | |
| $1.03 | $1.88 | $3.56 | +50% | Bullish | |
| $1.27 | $2.69 | $5.59 | +115% | Bullish | |
| $1.53 | $3.39 | $7.79 | +171% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.97 | $1.25 | $1.45 | +0.00% |
| September 2026 | $0.9547 | $1.15 | $1.45 | -7.77% |
| October 2026 | $1.00 | $1.23 | $1.57 | +6.54% |
| November 2026 | $1.01 | $1.25 | $1.62 | +1.93% |
| December 2026 | $0.9876 | $1.23 | $1.62 | -1.70% |
Click any year to see its month-by-month CVM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CVM is projected to trade between $0.97 and $1.62, averaging $1.25 — a potential gain of 0% from today's $1.25. A consolidation phase looks the most probable path here.
CEL-SCI Corporation's 2027 outlook centres on $1.62, within a $1.21 to $2.34 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, CVM could reach as high as $2.73, with a base case around $1.78 and support toward $1.26 — roughly +43% from $1.25. Buyers look set to stay in control over this stretch.
Expect CVM to range from $0.9536 to $2.27 through 2029. The $1.41 average target implies a +13% move from current prices. That is -21% versus the projected 2028 average. Price action looks broadly range-bound.
The CVM price prediction for 2030 points to an average of $1.42 (low $0.9202, high $2.36) — a potential gain of +13% on today's $1.25. A consolidation phase looks the most probable path here.
In 2031, CVM is projected to trade between $0.9125 and $2.51, averaging $1.46 — a potential gain of +17% from today's $1.25. That is up +3% on the projected 2030 average. Price action looks broadly range-bound.
CEL-SCI Corporation's 2032 outlook centres on $1.48, within a $0.895 to $2.63 range. That is up +2% on the projected 2031 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, CVM could reach as high as $3.64, with a base case around $2.00 and support toward $1.17 — roughly +60% from $1.25. Momentum favours further upside here.
Expect CVM to range from $1.13 to $3.72 through 2034. The $2.00 average target implies a +60% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The CVM price prediction for 2035 points to an average of $1.88 (low $1.03, high $3.56) — a potential gain of +50% on today's $1.25. Momentum favours further upside here.
In 2040, CVM is projected to trade between $1.27 and $5.59, averaging $2.69 — a potential gain of +115% from today's $1.25. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
CEL-SCI Corporation's 2050 outlook centres on $3.39, within a $1.53 to $7.79 range. That is up +26% on the projected 2040 average. That marks a +171% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CVM today (≈ 800 CVM) could be worth
$2,711.19
+$1,711.19 (+171%) by 2050 · US Dollar
Based on the average projected CVM price of $3.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVMwould be worth at today's price.
$1,000 invested in CVM on Jul 31, 2025 (≈ 122.249384 CVM) would be worth
$152.81
-$847.19 (-84.7%) today · 0.15× · US Dollar
Based on a CVM entry price of $8.18 vs. today's $1.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.18 | $1,059.32 | +5.9% |
| 1 month ago | $1.05 | $1,190.48 | +19.0% |
| 3 months ago | $2.28 | $548.25 | -45.2% |
| 6 months ago | $5.4 | $231.48 | -76.9% |
| 1 year ago | $8.18 | $152.81 | -84.7% |
| All time (5.0y) ago | $277.5 | $4.5 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVM forecast.
Our base-case forecast reaches $2.50 around 2040.
Implied market cap at $2.50: $43.69M
The multi-year forecast shows a gradual rise in the average price from 2026 onward, with 2026 at an average of $1.18 and a neutral outlook. By 2027 the average is $1.60 with a 35.2% ROI, rising further to an average of $2.68 by 2028 (ROI 44.3%), and peaking in the mid-year 2033–2035 window with bullish sentiment. Notable long-horizon milestones include 2030 at $1.37 (ROI 15.8%), 2040 at $2.55 (ROI 115.7%), and 2050 at $3.25 (ROI 175.7%), with bullish sentiment attached to the later years.
These figures imply meaningful upside potential over the next decade, albeit with significant variability and risk inherent to biotechnology equities.
Tap a question to reveal the answer.
2030 forecast shows min $0.8568, avg $1.37, max $2.34 with ROI 15.8% and sentiment NEUTRAL.
The outlook is mixed in the near term (neutral in 2026–2032), with stronger upside potential in later years (e.g., 2033 avg $1.96, ROI 66.2%; 2040 avg $2.55, ROI 115.7%; 2050 avg $3.25, ROI 175.7%), but these are estimates, not guarantees.
Yes. The 2030 max is $2.34, and the subsequent years show higher potential, with 2033 max $3.69, 2040 max $5.50, and 2050 max $7.48.
Current price is $1.18 and market capitalization is $20.62M.
The 30-day picture shows neutral sentiment with a price around $1.18, RSI 50, SMA50 $1.26, and SMA200 $4.40. The within-range supports at $0.97 and resistance at $1.41, with a 30-day range of $0.839 to $1.66.
CEL-SCI Corporation Community Discussion
0Share your CEL-SCI Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.